Next Article in Journal
Distinct Profiles of Cell-Free MicroRNAs in Plasma of Veterans with Post-Traumatic Stress Disorder
Next Article in Special Issue
Low Vitamin K Status Is Associated with Increased Elastin Degradation in Chronic Obstructive Pulmonary Disease
Previous Article in Journal
Risk and Prognostic Factors in Very Old Patients with Sepsis Secondary to Community-Acquired Pneumonia
Previous Article in Special Issue
Patterns and Predictors of Recovery from Poor Health Status Measured with the Chronic Obstructive Pulmonary Disease (COPD) Assessment Test in Patients with Stable COPD: A Longitudinal Study
Open AccessReview

Reassessing the Role of Eosinophils as a Biomarker in Chronic Obstructive Pulmonary Disease

1
Department of Cardiac, Thoracic, Vascular Sciences and Public Health; University of Padova, 35128 Padova, Italy
2
Respiratory Division, Meakins-Christie Laboratories; McGill University, Montreal H4A3J1, Canada
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work as first authors.
These authors contributed equally to this work as senior authors.
J. Clin. Med. 2019, 8(7), 962; https://doi.org/10.3390/jcm8070962
Received: 30 May 2019 / Revised: 18 June 2019 / Accepted: 27 June 2019 / Published: 2 July 2019
Blood eosinophils measurement, as proxy for tissue eosinophils, has become an important biomarker for exacerbation risk and response to inhaled corticosteroids (ICS) in Chronic Obstructive Pulmonary Disease (COPD). Its use to determine the pharmacological approach is recommended in the latest COPD guidelines. The potential role of blood eosinophils is mainly based on data derived from post-hoc and retrospective analyses that showed an association between increased blood eosinophils and risk of exacerbations, as well as mitigation of this risk with ICS. Yet other publications, including studies in real life COPD, do not confirm these assumptions. Moreover, anti-eosinophil therapy targeting interleukin (IL)-5 failed to reduce exacerbations in COPD patients with high blood eosinophils, which casts significant doubts on the role of eosinophils in COPD. Furthermore, a reduction of eosinophils might be harmful since COPD patients with relatively high eosinophils have better pulmonary function, better life quality, less infections and longer survival. These effects are probably linked to the role of eosinophils in the immune response against pathogens. In conclusion, in COPD, high blood eosinophils are widely used as a biomarker for exacerbation risk and response to ICS. However, much is yet to be learned about the reasons for the high eosinophil counts, their variations and their controversial effects on the fate of COPD patients. View Full-Text
Keywords: COPD; eosinophil; exacerbations COPD; eosinophil; exacerbations
Show Figures

Figure 1

MDPI and ACS Style

Tinè, M.; Biondini, D.; Semenzato, U.; Bazzan, E.; Cosio, M.G.; Saetta, M.; Turato, G. Reassessing the Role of Eosinophils as a Biomarker in Chronic Obstructive Pulmonary Disease. J. Clin. Med. 2019, 8, 962.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop